Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 8/20 | 0.46 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727036 | 0.93 | KDR (0.53) | ALKKDRPDGFRBFGFR1TLK2 | |
| SCHEMBL2117957 | 0.90 | MEN1 (0.46) | ALKKDRPDGFRBFGFR1KIT | |
| SCHEMBL2114496 | 0.88 | LRRK2 (0.42) | ALKKDRPDGFRBFGFR1TLK2 | |
| SCHEMBL2114228 | 0.85 | SRC (0.45) | ALKKDRPDGFRBFGFR1FLT3 | |
| SCHEMBL2114212 | 0.83 | KDR (0.44) | KDRPDGFRBFGFR1FLT3KIT | |
| SCHEMBL6722350 | 0.82 | KDR (0.51) | ALKKDRPDGFRBFGFR1TLK2 | |
| SCHEMBL722802 | 0.81 | ALK (0.52) | ALKKDRPDGFRBFGFR1TLK2 | |
| SCHEMBL6725660 | 0.81 | ALK (0.52) | ALKKDRPDGFRBFGFR1TLK2 | |
| SCHEMBL393773 | 0.81 | TLK2 (0.48) | KDRTLK2FLT3KITRET | |
| SCHEMBL2118294 | 0.80 | MEN1 (0.42) | ALKKDRPDGFRBFGFR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | claimed |
| EP-2246321-B1 | Delayed release rasagiline formulation | TEVA PHARMA (IL) | 2011-08-03 | — | — | EP | disclosed |
| EP-2308477-A1 | Delayed release rasagiline formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-04-13 | — | — | EP | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | ALK 4375/4885KDR 3687/4885PDGFRB 3475/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | ALK 110/4885KDR 71/4885PDGFRB 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.